Citation:Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011

Citation

Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology 2011 Nov;16(8):1210-20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21801275.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011 2	What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011 3	What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
3. What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC